HealthPro BioVentures
HealthPro BioVentures LLC provides strategic advisory and investment banking services to emerging companies in the healthcare and life sciences sectors, focusing solely on the challenging healthcare market. Their highly experienced staff includes financial professionals from healthcare investment banking and life sciences communities, aiming to help clients secure financial support and strategic partners to reach corporate objectives and maximize value.
Industries
Nr. of Employees
small (1-50)
HealthPro BioVentures
New City, New York, United States, North America
Services
Structuring and execution of equity and strategic financings; investor outreach to institutional healthcare funds, private equity, venture capital and high-net-worth individuals.
Buy-side and sell-side representation including target assessment, valuation, negotiation and transaction closing support.
Identification of partners for co-development, marketing and distribution; structuring and negotiating licensing and collaboration agreements, including cross-border deals.
Preparation of presentations and due-diligence materials, organization of investor/partner meetings, and support for negotiation and legal documentation.
Support for organizational strategy, growth planning and operational alignment to maximize corporate value in life sciences companies.
Identification and structuring of co-marketing and commercialization collaborations, including healthcare IT partnerships.
Structuring and execution of equity and strategic financings; investor outreach to institutional healthcare funds, private equity, venture capital and high-net-worth individuals.
Buy-side and sell-side representation including target assessment, valuation, negotiation and transaction closing support.
Identification of partners for co-development, marketing and distribution; structuring and negotiating licensing and collaboration agreements, including cross-border deals.
Preparation of presentations and due-diligence materials, organization of investor/partner meetings, and support for negotiation and legal documentation.
Support for organizational strategy, growth planning and operational alignment to maximize corporate value in life sciences companies.
Identification and structuring of co-marketing and commercialization collaborations, including healthcare IT partnerships.
Expertise Areas
- Capital formation and fundraising
- Mergers & acquisitions advisory
- Licensing and strategic partnering
- Strategic management and corporate development
Key Technologies
- Molecular diagnostics
- Biomarker-driven personalized medicine
- Drug delivery platforms (oral and transdermal)
- Therapeutic biologics and biopharmaceuticals
News & Updates
Announcement of Dr. James Kuo as managing director of the newly opened San Diego, CA office, expanding capabilities to include strategic management support alongside ongoing services.
India’s Transgene Biotek explores a strategic relationship with Armour Therapeutics of Toronto to co-develop drug candidates for reproductive cancers, including the development of AT-001 for hormone refractory prostate cancer.
OncoVista divests its majority holding of AdnaGen AG, with potential total sale proceeds up to $65 million contingent on milestones.
Abraxis and ProMetic enter license agreements for up to $295 million, with Abraxis making an initial $7 million equity investment in ProMetic.
SCOLR Pharma engages HealthPro as its financial advisor for prospective transactions and strategic partner evaluation.
MedeFile International engages HealthPro to structure strategic co-marketing partnerships and healthcare IT collaborations.
Announcement of Dr. James Kuo as managing director of the newly opened San Diego, CA office, expanding capabilities to include strategic management support alongside ongoing services.
India’s Transgene Biotek explores a strategic relationship with Armour Therapeutics of Toronto to co-develop drug candidates for reproductive cancers, including the development of AT-001 for hormone refractory prostate cancer.
OncoVista divests its majority holding of AdnaGen AG, with potential total sale proceeds up to $65 million contingent on milestones.
Abraxis and ProMetic enter license agreements for up to $295 million, with Abraxis making an initial $7 million equity investment in ProMetic.
SCOLR Pharma engages HealthPro as its financial advisor for prospective transactions and strategic partner evaluation.
MedeFile International engages HealthPro to structure strategic co-marketing partnerships and healthcare IT collaborations.